Those totals describe separate patient groups, so they do not show how many people had both conditions. In a 2025 explainer, Craig Beall, an associate professor of experimental diabetology, and Natasha MacDonald, a doctoral researcher in biochemistry, both at the University of Exeter, organized the evidence into 10 connections. <\/p>\n\n\n\n
Their message is clear, although not simple, because diabetes can affect the brain while changes linked to dementia may disturb the body\u2019s control of glucose.<\/p>\n\n\n\n
Blood sugar reaches the brain<\/h2>\n\n\n\n
The first connection is overall risk. A 2024 meta-analysis<\/a> covering more than 10 million people found that diabetes was associated with a 59% higher risk of dementia. Hypoglycemia, meaning dangerously low blood sugar, was linked to a 56% higher risk.<\/p>\n\n\n\n That does not mean dementia is inevitable for someone with diabetes, it means the odds are higher across large groups, and serious blood sugar swings may matter. Risk is not destiny.<\/p>\n\n\n\n The second and third connections involve insulin and fuel. Insulin resistance<\/a> happens when cells stop responding properly to the hormone that clears glucose from the blood, and brain insulin research suggests this can disrupt learning and memory. <\/p>\n\n\n\n The brain is only about 2% of body weight but uses roughly 20% of the body\u2019s energy, so poor glucose use in Alzheimer\u2019s can matter greatly, a pattern sometimes called \u201ctype-3 diabetes\u201d even though that is not a medical diagnosis.<\/p>\n\n\n\n The fourth connection turns the usual story around. People with Alzheimer\u2019s can have higher fasting glucose without diagnosed diabetes, while an animal study<\/a> found that Alzheimer\u2019s-like brain changes could push blood sugar upward. Animal results do not prove that Alzheimer\u2019s causes diabetes in people, but they suggest a two-way relationship.<\/p>\n\n\n\n Genes may add another layer. APOE4<\/a>, a version of a gene tied to higher Alzheimer\u2019s risk, can trap insulin receptors inside brain cells and make those cells less responsive. Picture a light switch stuck behind a wall, where the signal exists but the cell has trouble using it.<\/p>\n\n\n\n The fifth connection is blood-vessel damage<\/a>. High or sharply changing glucose can injure the brain\u2019s small vessels, reduce oxygen delivery, and weaken the blood-brain barrier, the protective filter that keeps many harmful substances out. That can encourage inflammation and vascular injury, two processes closely linked to dementia.<\/p>\n\n\n\n The sixth connection comes from an unlikely drug history. Memantine, now used to treat symptoms of moderate to severe Alzheimer\u2019s disease, was first studied as a diabetes medicine but did not lower blood sugar well enough. Researchers later discovered that it could act on brain signaling instead.<\/p>\n\n\n\n Science sometimes takes the scenic route. Memantine does not cure Alzheimer\u2019s or stop the disease, but its journey shows how work in one field can unexpectedly help another. A failed diabetes idea became a treatment that can ease dementia symptoms.<\/p>\n\n\n\n The seventh connection involves metformin<\/a>, a widely used type-2 diabetes drug. A 2023 cohort study<\/a> of 41,346 users found that people who stopped metformin for reasons unrelated to kidney problems had a 21% higher rate of dementia diagnosis. Because this was an observational study, it cannot prove that metformin protected the brain.<\/p>\n\n\n\n The eighth connection has drawn attention because it involves GLP-1 medicines<\/a> such as semaglutide, sold under brands including Ozempic and Wegovy. These drugs control blood sugar and appetite, and health-record studies have linked them to lower dementia rates among people with diabetes. Could the same medicine slow Alzheimer\u2019s itself?<\/p>\n\n\n\n The answer is not yet encouraging. In the EVOKE and EVOKE Plus phase 3 trials<\/a>, oral semaglutide did not slow worsening memory and thinking in people with early Alzheimer\u2019s, although some biological markers changed. Preventing a disease and treating it after symptoms begin are very different tests.<\/p>\n\n\n\n The ninth connection is insulin delivered through the nose, a route meant to carry the hormone toward the brain without sharply lowering blood sugar throughout the body. <\/p>\n\n\n\n Early work looked promising, but a randomized trial<\/a> of 289 adults found no cognitive or functional benefit in its main analysis, and delivery-device problems complicated the results. Interesting, yes, but proven, no.<\/p>\n\n\n\n The tenth connection involves SGLT2 inhibitors, pills that help the kidneys remove extra glucose through urine. In a 2025 comparison study<\/a> with 221,883 matched patient pairs, dementia was recorded in 2.7% of SGLT2 users and 3.6% of GLP-1 users. The researchers called for randomized trials before drawing firm conclusions.<\/p>\n\n\n\n For now, good diabetes care may help protect more than the heart and kidneys. Avoiding severe low blood sugar and limiting vessel damage may also support brain health, but no diabetes drug is a guaranteed shield and medications should not be changed for dementia prevention without medical advice. <\/p>\n\n\n\n The original expert article has been published in <\/a>The Conversation<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Could dementia begin with trouble outside the brain? Research increasingly suggests that blood sugar, insulin resistance, and damaged blood vessels … <\/p>\nRead More: Dementia may not begin in your brain at all: researchers now trace ten surprising ways diabetes could quietly set it off<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
![\"Blood](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/07\/diabetes-blood-sugar-dementia-risk-glucose-monitor.jpg\" "\\"\\"")
A blood glucose monitor and sugar cubes represent the growing body of research linking diabetes, insulin resistance, and blood sugar control to long-term brain health and dementia risk.<\/figcaption><\/figure>\n\n\n\nThe link may run both ways<\/h2>\n\n\n\n
Read More: A pediatric oncologist who has examined 200,000 children says the same thing happens to every family when a child gets cancer<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Old drugs opened new doors<\/h2>\n\n\n\n
Weight-loss drugs meet a reality check<\/h2>\n\n\n\n
Read More: Frida Kahlo, painter: “Where you cannot love, do not linger”: why this line became a self-worth mantra you might repeat too<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Newer pills may offer another clue<\/h2>\n\n\n\n